Knowles Julius reported grant involving 7,433 derivative units of Keros Therapeutics, Inc. at $0.00 for $0 on Jun 3, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Jun 5, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
7,433Stock Option (right to buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
7,433Direct
Trade date
Jun 3, 2026Grant
Filed
Jun 5, 2026, 4:15 PM ET2-day reporting delay
Accession
0001808365-26-000002Code A · Transaction 100087
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Jun 3, 2026Grant7,142$0.00$0Trade 100086
2 transaction rows in this filing. Joint filers share the same rows.

KROS price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
KROS · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +14%1w ago +9.8%1d ago +2.4%
Returns since7d −1.5%30d +9.3%90d180d1y

Footnotes in full

F1: Represents a restricted stock unit ("RSU") award. The RSUs fully vest on the earlier of (A) June 3, 2027 and (B) the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. F2: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. F3: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. F4: The option shall vest in equal quarterly installments over the 12 months following June 3, 2026, provided that the grant will in any case be fully vested on the date of Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.